Status:
COMPLETED
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Lead Sponsor:
Pfizer
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). MM is a type of cancer that begins in plasma cells (white bloo...
Detailed Description
This study aims to contextualize the outcomes of Study C1071003 by comparing a priori specified clinical effectiveness of patients treated with elranatamab using patient-level data from study C1071003...
Eligibility Criteria
Inclusion
- Aged 18 years and older at index date
- Diagnosis of MM
- Measurable disease according to IMWG criteria
- ECOG performance status ≤2
- Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 treatment (ie, triple-class refractory \[TCR\])
- At least 1 treatment according to G-BA's definition of standard of care following their TCR eligibility
Exclusion
- Acute plasma cell leukemia
- Amyloidosis
- Smoldering MM
- Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
- Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ
- Administration with an investigational drug within 30 days prior to index
- 1st treatment following TCR eligibility not according to G-BA's definition of standard of care
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
633 Patients enrolled
Trial Details
Trial ID
NCT06504524
Start Date
September 1 2023
End Date
May 31 2024
Last Update
June 27 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10001
2
Pfizer
Berlin, Germany